Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States

被引:109
作者
Ahuja, TS
Grady, J
Khan, S
机构
[1] Univ Texas, Med Branch, Dept Med, Div Nephrol, Galveston, TX 77550 USA
[2] Univ Texas, Med Branch, Dept Prevent Med & Community Hlth, Div Epidemiol & Biostat, Galveston, TX 77550 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷 / 07期
关键词
D O I
10.1097/01.ASN.0000019773.43765.BF
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
HIV-infected patients with end-stage renal disease have a very high morbidity and mortality. In the last decade, survival of HIV-infected patients in the United States has remarkably improved. To determine whether similar improvement in survival has occurred in HIV-infected dialysis patients, their survival was evaluated by using the United States Renal Data System database. Survival of HIV-infected dialysis patients in the United States was determined and the influence of year of initiation of dialysis, and demographic characteristics on the survival were analyzed by the Kaplan-Meier method. The effects of above variables on survival were also examined in a Cox proportional hazards model. Identified were 6166 HIV-infected patients with end-stage renal disease who received dialysis in the United States. Eighty-nine percent of the patients were black, 7.4% white, and 3% other. From 1990 to 1999, 1-yr survival of HIV-infected patients on dialysis improved from 56 to 74%, and the annual death rates declined from 458 deaths to 240 deaths per 1000 patient-years. The hazard ratio declined significantly in patients who initiated dialysis in years 1999-2000 compared with patients who initiated dialysis less than or equal to 1990 (hazard ratio, 0.49; 95% confidence interval, 0.40 to 0.60). Survival of HIV-infected dialysis patients has remarkably improved in the United States.
引用
收藏
页码:1889 / 1893
页数:5
相关论文
共 29 条
[1]   Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients [J].
Ahuja, TS ;
Borucki, M ;
Grady, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (03) :574-580
[2]   Is the prevalence of HIV-associated nephropathy decreasing? [J].
Ahuja, TS ;
Borucki, M ;
Funtanilla, M ;
Shahinian, V ;
Hollander, M ;
Rajaraman, S .
AMERICAN JOURNAL OF NEPHROLOGY, 1999, 19 (06) :655-659
[3]   PLASMA INTERLEUKIN-1 ACTIVITY DURING HEMODIALYSIS - THE INFLUENCE OF DIALYSIS MEMBRANES [J].
BINGEL, M ;
LONNEMANN, G ;
KOCH, KM ;
DINARELLO, CA ;
SHALDON, S .
NEPHRON, 1988, 50 (04) :273-276
[4]  
BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231
[5]  
*CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861
[6]   PATHOLOGY OF HIV-ASSOCIATED NEPHROPATHY - A DETAILED MORPHOLOGIC AND COMPARATIVE-STUDY [J].
DAGATI, V ;
SUH, JI ;
CARBONE, L ;
CHENG, JT ;
APPEL, G .
KIDNEY INTERNATIONAL, 1989, 35 (06) :1358-1370
[7]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[8]  
FEINFELD DA, 1989, CLIN NEPHROL, V32, P221
[9]   INFLUENCE OF UREMIA AND HEMODIALYSIS ON CIRCULATING INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA [J].
HERBELIN, A ;
NGUYEN, AT ;
ZINGRAFF, J ;
URENA, P ;
DESCAMPSLATSCHA, B .
KIDNEY INTERNATIONAL, 1990, 37 (01) :116-125
[10]  
Ifudu O, 1997, AM J KIDNEY DIS, V29, P549, DOI 10.1016/S0272-6386(97)90336-X